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Abstract 
Renal medullary carcinoma (RMC) is a rare
and  highly  aggressive  malignancy  arising
from the renal medulla and found mostly in
patients  with  sickle  cell  trait.  RMC  usually
presents with widely metastatic disease. We
describe  a  young  man  diagnosed  with
metastatic  RMC  who  sustained  a  complete
response to systemic chemotherapy but devel-
oped  brain  metastases  with  leptomeningeal
involvement  and  subsequently  had  a  partial
response to brain irradiation. The use of radi-
ation in the management of RMC is reviewed.
Due  to  the  apparent  propensity  for  RMC  to
spread to the central nervous system, prophy-
lactic treatment such as craniospinal irradia-
tion  should  be  considered  along  with
chemotherapy  in  patients  with  metastatic
RMC to potentially improve the progression-
free interval. 
Introduction
Renal  medullary  carcinoma  (RMC)  is  an
aggressive  malignancy  seen  primarily  in
young African-American patients with sickle
cell trait. We report the case of an 11 year old
with metastatic RMC without central nervous
system (CNS) involvement at diagnosis who
developed brain metastases with evidence of
leptomeningeal spread 11 months after having
a complete response (CR) to 9 cycles of multi-
agent chemotherapy. Brain radiation provided
the  patient  with  palliation,  and  his  brain
metastases shrank as a result of the radiation.
The use of radiation in the management of
RMC  is  reviewed,  and  based  on  the  likely
propensity for RMC to spread to the CNS, the
use of CNS prophylactic therapy such as cran-
iospinal irradiation (CSI) should be consid-
ered in patients with metastatic RMC.
Case Report
An 11 year old African-American male with-
out medical problems but a known diagnosis of
sickle-cell  trait  initially  presented  with  back
pain and cough as well as weight loss and neck
swelling.  A  computed  tomography  (CT)  scan
showed  a  large  left  kidney  mass,  measuring
7.8ﾥ5.6ﾥ5.8 cm, wide-spread lymphadenopathy,
bilateral pleural effusions and too numerous to
count  liver  and  lung  nodules.  A  bone  scan
showed widespread bone metastatic disease. Of
note, a brain CT scan was negative for disease.
A biopsy confirmed RMC. He began treatment
with  paclitaxel,  gemcitabine  and  carboplatin
(PGC).  The  patient’s  tumor  responded  in  all
sites, and after three cycles of chemotherapy, he
had a left nephrectomy, retroperitoneal lymph
node dissection, and thoracoscopic removal of
the  pulmonary  nodules.1 Pathologic  examina-
tion of all removed tissue showed no evidence of
tumor, and radiologic evaluation was negative
for disease. The patient underwent an addition-
al  six  cycles  (nine  total)  of  combination
chemotherapy. He remained disease-free for 11
months off therapy before presenting with per-
sistent headaches, left leg weakness and hyper-
reflexia.  A  CT  scan  showed  a  right  parietal
abnormality and leptomeningeal enhancement.
He was given IV dexamethasone, admitted to
the hospital and underwent a magnetic reso-
nance imaging (MRI) which showed 3 masses
in  the  right  parietal  lobe  with  surrounding
peripheral edema arising from the interhemi-
spheric fissure (Figure 1 A-B). A CT scan of the
chest/abdomen/pelvis and spinal MRI were neg-
ative for disease suggesting his relapsed was
only in the CNS. The patient started radiation
therapy as well as temozolomide orally at 75
mg/m2 daily.  Initially,  he  began  5  fractions
(250cGy each) of whole brain radiation via a
helmet field down to C2. Then, he began 10 frac-
tions with an integrated boost plan to treat the
remainder of the brain parenchyma, and he was
given an additional 200 cGy x 10 doses with the
gross tumor receiving 300 cGy in 10 fractions. In
total, the patient received 3250 cGy in 15 frac-
tions to the whole brain, and 4250 cGy in 15
fractions to the gross tumor. He tolerated the
radiation well with only mild nausea during the
second  week  of  therapy.  The  patient  had
improvement in his weakness and headaches,
and  his  dexamethasone  was  successfully
weaned  off  one  week  after  completing  treat-
ment. A repeat MRI one month after completing
radiation showed decrease in the size of the
lesions  and  significantly  decreased  edema
(Figure 1C-D). One month later, the patient pre-
sented with worsening headache and malignant
cells in the cerebrospinal fluid were confirmed
via  lumbar  puncture.  The  patient  was  dis-
charged into the care of hospice and died at
home 1.5 months later. 
Discussion
RMC  is  a  rare  and  clinically  aggressive
tumor first described in 1997 and thought to
arise from the renal collecting duct. RMC most
commonly occurs in patients with sickle-cell
trait.2 There have now been three reports of
long-term  survivors  of  RMC  who  presented
with localized tumors and underwent a com-
plete resection.3-5 However, most patients pres-
ent with metastatic disease, and have tradi-
tionally had a very poor prognosis. The most
common sites of metastatic disease at diagno-
sis include lung, retroperitoneal or mediasti-
nal lymph nodes, bone and liver. There have
also been several cases that initially presented
with metastatic brain or spinal-cord lesions.6-8
In one review of 64 patients with metastatic
renal cell carcinoma other than the clear-cell
type (including RMC, papillary, chromophobe
and  unclassified),  only  2  patients  (3%)  pre-
sented with metastatic brain lesions. In con-
trast, 28 patients (41%) had lung and 30 (47%)
had  retroperitoneal  lymph  node  disease  at
diagnosis.9 Fifty-eight of 61 patients with RMC
had metastases present at the time of diagno-
sis.10 Although brain metastases at presenta-
tion in patients with RMC are uncommon, a
brain MRI at the time of diagnoses would rule
out occult metastases.
Initial  reports  of  RMC  revealed  a  median
survival  of  14  weeks  after  diagnosis.2,5,11
However,  there  have  been  several  recent
reports  that  the  combination  chemotherapy
regimen  of  PGC  or  cisplatin  is  active  in
patients  with  RMC  and  may  prolong  sur-
vival.1,6,12,13 In addition to our patient who had a
CR to PGC, a subsequent patient at our institu-
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tion with RMC has had a CR with this same
chemotherapy regimen. 
There are now three reports in the literature
of patients (including the report presented in
this  paper)  who  responded  well  to  systemic
chemotherapy outside of the CNS but devel-
oped  or  had  worsening  CNS  disease.1,6,12
Strouse et al. reported a case of a 17-year old
African-American  male  with  a  right  kidney
RMC and multiple sites of bony metastatic dis-
ease  at  presentation.  He  underwent  initial
treatment with carboplatin alone and had sig-
nificant  improvement  in  the  size  of  his
tumors. After 27 weeks of therapy, the patient
developed  neck  pain  and  headache.  An  MRI
showed multiple brain lesions consistent with
metastatic disease. Further workup showed no
evidence  of  disease  outside  the  CNS.  The
patient received palliative external beam radi-
ation  to  the  brain  (3750  cGy)  and  thoracic
spine (3000 cGy) while continuing the carbo-
platin therapy. Two months after completion of
the radiotherapy, he had worsening back pain
and evidence of progression of the brain and
spinal  metastases.12 Our  patient,  similar  to
this patient developed recurrent disease in the
CNS after treatment with a carboplatin-based
regimen.
Schaeffer et al. described a case of a 35-year
old African-American man with sickle-cell trait
that developed a right kidney RMC and multi-
ple  metastatic  lesions  in  mediastinal  lymph
nodes,  lung  and  brain  as  well  as  an  intra  -
cardiac  mass.  The  patient  underwent  seven
cycles of PGC with initial reduction in the size
of the brain and lung lesions. After 6 months of
therapy, the patient complained of headache
and a repeat MRI showed an increase in size of
the brain metastasis. The patient underwent
palliative brain irradiation and started a sal-
vage chemotherapy regimen with adriamycin
and  gemcitabine  with  an  initial  excellent
response  that  lasted  9  months.  The  patient
eventually  relapsed  in  the  lung  and  medi-
astinum and died 25 months after his initial
diagnosis.6
Limited  information  has  been  published
about the use of radiation for the treatment of
RMC. Table 1 reviews the use of radiation in
RMC in the published literature. Most investi-
gators have used radiation for palliative pain
control in metastatic sites, although Karaman
et al. and Stahlschmidt et al. report the use of
abdominal radiation as an adjunct to surgical
resection  and  chemotherapy  with  little  suc-
cess.14,15 Reports  of  palliative  radiation  for
bone metastases have described a reduction in
pain  and  some  decrease  in  the  size  of
lesions.10,13,16 Avery et al. noted no response in
pulmonary  metastases  to  lung  irradiation.8
However,  in  addition  to  Strouse  et  al. and
Schaeffer et al., we noted a decreased size in
brain  metastases  in  our  patient  after  brain
irradiation  (Figure  1).6,12 Although  the  evi-
dence is mixed, it appears that RMC is radio-
sensitive in many cases. There have been no
reports  of  prophylactic  CSI  in  RMC.  For
patients with residual CNS tumor after CNS
fractionated radiation therapy, there may be a
role  for  stereotactic  radiosurgical  boost,
although there is no reported data on radio-
surgery in this rare disease.
Upfront prophylaxis with either intrathecal
chemotherapy  or  CSI  in  malignancies  that
tend  to  recur  in  the  CNS  may  prevent  the
development of CNS disease. The routine use
of CNS prophylaxis improved survival for child-
hood  acute  lymphoblastic  leukemia  dramati-
cally.17 Additionally, the use of prophylactic cra-
nial irradiation in limited-stage small cell lung
cancer has been shown to decrease the occur-
rence of CNS metastases, with a 5.4% survival
advantage in those patients who had received
irradiation (20.7% survival at 3 years in the
treated  group  versus  15.3%  in  the  control
group).18
Based on our patient’s impressive response
to systemic therapy, and the fact that he never
relapsed outside of the CNS, we speculate that
the chemotherapeutic agents that he received
may not have crossed the blood-brain barrier
adequately to eradicate microscopic metastatic
cells in the CNS that were likely present at
diagnosis  but  not  apparent  on  his  initial
Case Report
Figure 1. Magnetic resonance imaging of the brain, showing T1-post contrast (images on
the left, A and C) as well as T2 flair images (images on the right, B and D). Images A and
B demonstrate metastatic lesions in the right parietal lesion prior to radiation therapy.
Images C and D were taken one month after radiation therapy and demonstrate an approx-
imately 1/3 decrease in the size of the brain metastases as well as decrease in the surround-
ing brain edema.[page 102] [Rare Tumors 2011; 3:e32]
metastatic disease work-up. Prior to the intro-
duction of the active combination of PGC, sur-
vival  from  RMC  was  generally  measured  in
weeks.  With  this  new  combination  of
chemotherapeutic agents, patients are having
partial and, at times, complete responses. We
surmise  that  local  CNS  recurrence  may
become  a  more  common  problem  as  these
agents  poorly  cross  the  blood-brain  barrier.
CNS  prophylaxis  such  as  CSI,  intrathecal
chemotherapy,  or  a  combination  of  cranial
radiation  and  intrathecal  chemotherapy  may
prevent or delay CNS recurrence. The majority
of RMC patients present with widely metastat-
ic  disease  and  microscopic  malignant  cells
may be more likely to respond completely to
radiation  therapy  than  bulky  metastatic  dis-
ease. Ideally, a randomized controlled trial with
and without CSI in RMC would be conducted to
definitively  answer  the  question  of  whether
CSI would be helpful to decrease the incidence
of CNS recurrence. Due to the rarity of this
tumor type, it is unlikely that a randomized
trial can be done in a timely fashion. Radiation
appears to be well tolerated in patients with
RMC and the potential benefits may outweigh
the risks in this group of patients. Therefore,
CNS prophylactic therapy should be considered
in patients with metastatic RMC to potentially
improve the progression-free interval.
References
1. Walsh A, Kelly DR, Vaid YN, et al. Complete
response to carboplatin, gemcitabine, and
paclitaxel  in  a  patient  with  advanced
metastatic  renal  medullary  carcinoma.
Case Report
Table 1. Summary of the available literature describing the use of radiation therapy for the treatment of renal medullary carcinoma.
Authors Case Chemotherapy  Radiated location Response  Survival  
regimen and dose (if known) to radiation time,
diagnosis
to death
Schaeffer et al.6 35 yo male with gross hematuria,  Initial: 7 cycles carbo,  Palliative to brain Improvement in  25 mo
s/p laparoscopic RN, nodes +.  GEM, paclitaxel brain lesions
2 weeks post surgery developed  Salvage: adria, GEM
mets to skin, mouth, lungs, brain, 
and heart.  Enlargement of brain 
nodule post chemotherapy
Bell13 20 yo male with flank pain, fever,  10 cycles paclitaxel,  Palliative to bony mets Improved pain  10.5 mo
weight loss and large right  GEM, cis control
kidney mass
Avery et al.8 26 yo with right kidney mass  a-interferon x 9 doses Palliative to lung (3000 cGy) No response 3 mo
with mets to lung, diaphragm  (no response)
and lymph nodes 
Dimashkieh et al19 40 yo with lymphadenopathy,  Unknown Unknown Little benefit 5 mo
CT showed 2 masses in R kidney 
metastatic to supraclavicular LNs
Karaman et al.14 7 yo right kidney mass, s/p RN,  VCN, actino-D, VP-16 Upfront 2160 cGy to   Not good 4.5 mo
mets at diagnosis to LN, operation region, 1080 cGy  
bones and lungs to tumor region as boost
Simpson et al10 5 cases:
1. s/p RN 1. MVAC/Carbo/VP16 1. All tumor sites 1.  Complete (first    1.  49 wks
2. s/p RN 2. 5FU/GEM/ THAL,  taxol/THAL 2. Bone line),  partial 2.  52 wks
3. no RN 3. MVAC 3. Brain (second line) 3   63 wks
4. s/p RN 4. MVAC,GEM/  4. Tumor sites     2.  Mixed (response   4.  64 wks
5. s/p RN docetaxel, VP16/    5. Lung at existing sites  5.  unk
Carbo/ifos,   with new mets)
Thal/capecitabine 3.  Partial (first line)
5. Topotecan/adria 4.  Partial (first line),
mixed (second line), 
progressive(salvage)
5.  Progressive  
disease
Watanabe et al.5 19 yo with hematuria x 5 months,  GEM/cis Unknown Poor 5 mo
mets to lungs at diagnosis
Rathmell et al.16 48 yo with gross hematuria,  Initial: sunitinib, no response Palliative  to painful  Improvement in pain Alive at time
CT showed right  kidney mass,  Second-line:  MVAC x 7 cycles bony met of publication
s/p RN, mets to LNs and liver
Strouse et al.12 17 yo with right RN. 3 months later  Carbo Palliative to brain (3750 cGy) Partial improvement 12 mo
presented with mets to lung,  and thoracic spine (3000 cGy)
lymph nodes, bone and liver
Stahlschmidt et al.15 14 yo with sickle-cell disease  MVAC x 6 cycles Upfront to abdominal   Remission x 4 months 49 wks
presented with weight loss  sites of disease 
and abd pain. U/S showed  (4500 cGy)
mass in left kidney, RN, + 
paraaortic LNs
actino-D, actinomycin-D; adria, adriamycin; cis, cisplatin; carbo, carboplatin; CT, computerized tomography; GEM, gemcitabine; ifos, ifosphamide; LN, lymph node; mets, metastases; MVAC, methotrexate, vinblastine,
doxorubicin and cisplatin; RN, radical nephrectomy; SFU, S-fluorouracil; THAL, thalidomide; U/S: ultrasound; VCN, vincristine; VP-16, etoposide; yo, year old.[Rare Tumors 2011; 3:e32] [page 103]
Pediatr Blood Cancer 2010;55:1217-20.
2. Davis CJ, Jr., Mostofi FK, Sesterhenn IA.
Renal medullary carcinoma. The seventh
sickle cell nephropathy. Am J Surg Pathol
1995;19:1-11.
3. Khan A, Thomas N, Costello B, et al. Renal
medullary  carcinoma:  sonographic,  com-
puted  tomography,  magnetic  resonance
and  angiographic  findings.  Eur  J  Radiol
2000;35:1-7.
4. Selby DM, Simon C, Foley JP, et al. Renal
medullary carcinoma: can early diagnosis
lead  to  long-term  survival?  J  Urol
2000;163:1238.
5. Watanabe IC, Billis A, Guimaraes MS, et al.
Renal  medullary  carcinoma:  report  of
seven  cases  from  Brazil.  Mod  Pathol
2007;20:914-20.
6. Schaeffer EM, Guzzo TJ, Furge KA, et al.
Renal  medullary  carcinoma:  molecular,
pathological  and  clinical  evidence  for
treatment  with  topoisomerase-inhibiting
therapy. BJU Int 2010;106:62-5.
7. Cheng  JX,  Tretiakova  M,  Gong  C,  et  al.
Renal medullary carcinoma: rhabdoid fea-
tures and the absence of INI1 expression
as  markers  of  aggressive  behavior.  Mod
Pathol 2008;21:647-52.
8. Avery RA, Harris JE, Davis CJ, Jr., et al.
Renal  medullary  carcinoma:  clinical  and
therapeutic aspects of a newly described
tumor. Cancer 1996;78:128-32.
9. Motzer  RJ,  Bacik  J,  Mariani  T,  et  al.
Treatment outcome and survival associat-
ed with metastatic renal cell carcinoma of
non-clear-cell  histology.  J  Clin  Oncol
2002;20:2376-81.
10. Simpson  L,  He  X,  Pins  M,  et  al.  Renal
medullary carcinoma and ABL gene ampli-
fication. J Urol 2005;173:1883-8.
11. Hakimi  AA,  Koi  PT,  Milhoua  PM,  et  al.
Renal  medullary  carcinoma:  the  Bronx
experience. Urology 2007;70:878-82.
12. Strouse  JJ,  Spevak  M,  Mack  AK,  et  al.
Significant  responses  to  platinum-based
chemotherapy in renal medullary carcino-
ma. Pediatr Blood Cancer 2005;44:407-11.
13. Bell  MD.  Response  to  paclitaxel,  gemc-
itabine, and cisplatin in renal medullary
carcinoma.  Pediatr  Blood  Cancer
2006;47:228.
14. Karaman S, Celkan T, Kuruoglu S, et al.
Renal medullary carcinoma case present-
ing with abdominal mass. Turkish Journal
of Cancer 2005;35:96-8.
15. Stahlschmidt  J,  Cullinane  C,  Roberts  P,
Picton  SV.  Renal  medullary  carcinoma:
prolonged  remission  with  chemotherapy,
immunohistochemical  characterisation
and  evidence  of  bcr/abl  rearrangement.
Med Pediatr Oncol 1999;33:551-7.
16. Rathmell WK, Monk JP. High-dose-intensi-
ty  MVAC  for  Advanced  Renal  Medullary
Carcinoma:  Report  of  Three  Cases  and
Literature  Review.  Urology  2008;72:659-
63.
17. Pui CH, Thiel E. Central nervous system
disease in hematologic malignancies: his-
torical  perspective  and  practical  applica-
tions. Semin Oncol 2009;36:S2-S16.
18. Stinchcombe TE, Gore EM. Limited-stage
small cell lung cancer: current chemora-
diotherapy  treatment  paradigms.
Oncologist 2010;15:187-95.
19. Dimashkieh H, Choe J, Mutema G. Renal
medullary carcinoma: a report of 2 cases
and review of the literature. Arch Pathol
Lab Med 2003;127:e135-8.
Case Report